Search research articles
Contact Us
Filters
Showing results (81-90 of 102) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Pharmacology Research & Perspectives
|
August 5, 2022
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP
Emily M J Fennell, Lucas J Aponte-Collazo, Joshua D Wynn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
The Journal of Experimental Medicine
|
January 31, 2020
Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia
Juan Tang, Sha Tu, Guoxin Lin, et al.
Research Square
|
June 5, 2026
SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancer
Aanika B Warner, Britanny B Solarz, Miroslava Belyov, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Oncotarget
|
May 3, 2018
ONC201 kills breast cancer cells <i>in vitro</i> by targeting mitochondria
Yoshimi Endo Greer, Natalie Porat-Shliom, Kunio Nagashima, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 26, 2023
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Sarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Biorxiv : the Preprint Server for Biology
|
January 8, 2024
NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer
Lisa A Ridnour, William F Heinz, Robert Ys Cheng, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 102) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Pharmacology Research & Perspectives
|
August 5, 2022
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP
Emily M J Fennell, Lucas J Aponte-Collazo, Joshua D Wynn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 2020
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J Lampert, Alexandra Zimmer, Michelle Padget, et al.
The Journal of Experimental Medicine
|
January 31, 2020
Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia
Juan Tang, Sha Tu, Guoxin Lin, et al.
Research Square
|
June 5, 2026
SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancer
Aanika B Warner, Britanny B Solarz, Miroslava Belyov, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Oncotarget
|
May 3, 2018
ONC201 kills breast cancer cells <i>in vitro</i> by targeting mitochondria
Yoshimi Endo Greer, Natalie Porat-Shliom, Kunio Nagashima, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 26, 2023
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Sarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Biorxiv : the Preprint Server for Biology
|
January 8, 2024
NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer
Lisa A Ridnour, William F Heinz, Robert Ys Cheng, et al.
Page
of 11